View of The substantiation of the cost optimization for ER(+) HER2(−) breast cancer hormone therapy based on the results of the cost minimization pharmacoeconomic analysis

Return to Article Details The substantiation of the cost optimization for ER(+) HER2(−) breast cancer hormone therapy based on the results of the cost minimization pharmacoeconomic analysis Download Download PDF